• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

11.12.17: Not intended for U.S. and UK Media
Bayer's rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery diseaseThe rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack / The application for marketing approval is based on the COMPASS studymehr ...
Source: Bayer IR Newsfeed: Events - December 10, 2017 Category: Pharmaceuticals Source Type: news

06.11.17: Not intended for U.S. and UK Media
Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines AgencyThe rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack (1) / The application for marketing approval is based on the COMPASS study / If approved, the rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin low dose once daily, will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated for this patient populationmehr ...
Source: Bayer IR Newsfeed: Events - November 5, 2017 Category: Pharmaceuticals Source Type: news

27.08.17: Not intended for U.S. and UK Media - Data from COMPASS study, including 27,395 patients, presented at ESC Congress 2017:
Bayer's Xarelto® significantly lowered the combined risk of stroke, cardiovascular death and heart attack in patients with chronic coronary or peripheral artery disease by 24%Importantly, rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin 100 mg once daily showed an unprecedented 42% relative risk reduction in stroke and 22% in cardiovascular death compared with aspirin 100 mg once daily alone / Bleeding rates were low, and while major bleeding was increased, notably there was no significant increase in intracranial or fatal bleeding / This combination regimen demonstrated a substantial improvement in net clinica...
Source: Bayer IR Newsfeed: Events - August 26, 2017 Category: Pharmaceuticals Source Type: news

08.02.17: Not intended for U.S. and UK Media
Phase III COMPASS study with Bayer's Rivaroxaban in Patients with Coronary or Peripheral Artery Disease Shows Overwhelming Efficacy and Meets Primary Endpoint Early Coronary or peripheral artery disease patients carry significant risk of fatal or debilitating myocardial infarction and stroke / Rivaroxaban is the only non-vitamin K antagonist oral anticoagulant currently under assessment in this high risk patient populationmehr ...
Source: Bayer IR Newsfeed: Events - February 7, 2017 Category: Pharmaceuticals Source Type: news